The present invention relates to at least one novel chimeric, humanized or
CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody,
including isolated nucleic acids that encode at least one such anti-IL-6
antibody, vectors, host cells, transgenic animals or plants, and methods
of making and using thereof, including therapeutic compositions, methods
and devices.